Trading Report: Today: Edwards Lifesciences Corp. (EW) Position Increased by Sigma Planning Corp

Today: Edwards Lifesciences Corp. (EW) Position Increased by Sigma Planning Corp

Sigma Planning Corp boosted its stake in shares of Edwards Lifesciences Corp. (NYSE:EW) by 173.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,138 shares of the medical research company’s stock after buying an additional 4,529 shares during the period. Sigma Planning Corp’s holdings in Edwards Lifesciences Corp. were worth $861,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Pennsylvania Trust Co increased its stake in shares of Edwards Lifesciences Corp. by 46.8% in the second quarter. Pennsylvania Trust Co now owns 43,063 shares of the medical research company’s stock valued at $4,295,000 after buying an additional 13,728 shares during the period. Farmers & Merchants Investments Inc. increased its stake in shares of Edwards Lifesciences Corp. by 21.7% in the second quarter. Farmers & Merchants Investments Inc. now owns 22,756 shares of the medical research company’s stock valued at $2,269,000 after buying an additional 4,051 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Edwards Lifesciences Corp. by 4.7% in the second quarter. Nisa Investment Advisors LLC now owns 80,471 shares of the medical research company’s stock valued at $8,025,000 after buying an additional 3,595 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Edwards Lifesciences Corp. by 26.0% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,580 shares of the medical research company’s stock valued at $2,850,000 after buying an additional 5,900 shares during the period. Finally, Eqis Capital Management Inc. increased its stake in shares of Edwards Lifesciences Corp. by 3.1% in the second quarter. Eqis Capital Management Inc. now owns 16,903 shares of the medical research company’s stock valued at $1,686,000 after buying an additional 506 shares during the period. Institutional investors own 83.08% of the company’s stock.

Edwards Lifesciences Corp. (NYSE:EW) opened at 85.80 on Monday. The firm has a market capitalization of $18.35 billion, a price-to-earnings ratio of 33.91 and a beta of 0.71. The firm has a 50-day moving average of $100.51 and a 200 day moving average of $106.69. Edwards Lifesciences Corp. has a 12-month low of $72.20 and a 12-month high of $121.75.

Edwards Lifesciences Corp. (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.68. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. The firm earned $739.40 million during the quarter, compared to analysts’ expectations of $749.14 million. During the same quarter last year, the business earned $0.54 earnings per share. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. On average, equities analysts predict that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

Several brokerages have weighed in on EW. Leerink Swann restated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Evercore ISI restated a “hold” rating and issued a $115.00 target price on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Morgan Stanley restated a “buy” rating and issued a $140.00 target price on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Credit Suisse Group AG set a $116.00 price objective on shares of Edwards Lifesciences Corp. and gave the stock a “buy” rating in a research note on Thursday, August 18th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $140.00 price objective on shares of Edwards Lifesciences Corp. in a research note on Thursday, August 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $117.68.

In other Edwards Lifesciences Corp. news, VP Donald E. Bobo, Jr. sold 18,000 shares of the firm’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $115.78, for a total transaction of $2,084,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Larry L. Wood sold 13,257 shares of the firm’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $119.27, for a total transaction of $1,581,162.39. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Corp. Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Related posts

Leave a Comment